Doubling Up For Speed In Biomanufacturing: How To Complement Your In-House Resources With A CDMO For Parallel Operations

Drug development is a high-stakes endeavor where every decision can influence success or failure long before a therapy reaches the market. Traditional approaches often operate in silos, limiting collaboration and slowing progress. To overcome these challenges, many organizations are turning to parallel operations, a model that enables simultaneous process development and cGMP manufacturing through external CDMO partnerships while building internal capabilities. This strategy not only mitigates risk but also reduces capital costs and accelerates speed to market, giving companies a competitive edge.

Read the full article to discover how parallel operations can transform biomanufacturing strategies and position your organization for success in an increasingly demanding landscape.